A Phase 1, Open-label, Single-arm Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of TNFa and IL-2 Coding Oncolytic Adenovirus TILT-123 in Combination With Lymphocyte-depleting Chemotherapy and Tumor-infiltrating Lymphocytes in Melanoma Patients.

This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.

开始日期2025-06-01

申办/合作机构

TILT Biotherapeutics Oy

NCT06125197

/ Recruiting临床1期

A Phase I Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab in Patients With Immune Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer

This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.

开始日期2024-07-23

申办/合作机构

TILT Biotherapeutics Oy

[+1]

NCT05222932

/ Recruiting临床1期

A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and IL-2 Coding Oncolytic Adenovirus TILT-123 and Avelumab in Solid Tumor Patients (Melanoma and SCCHN) Refractory to or Progressing After Anti-PD(L)1

This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.

开始日期2023-03-08

申办/合作机构

TILT Biotherapeutics Oy

100 项与 Igrelimogene litadenorepvec 相关的临床结果

登录后查看更多信息

100 项与 Igrelimogene litadenorepvec 相关的转化医学

登录后查看更多信息

100 项与 Igrelimogene litadenorepvec 相关的专利（医药）

登录后查看更多信息

项与 Igrelimogene litadenorepvec 相关的文献（医药）

2025-03-01·Cell Reports Medicine

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma

Article

作者: Vestergaard, Cecilie ; Albieri, Benedetta ; Cervera-Carrascon, Victor ; Kistler, Claudia ; Quixabeira, Dafne C A ; Lorentzen, Torben ; Santos, João M ; Clubb, James H A ; Ellebaek, Eva ; Holmstroem, Rikke B ; Dreno, Brigitte ; Borch, Troels H ; Jirovec, Elise ; Khammari, Amir ; Haybout, Lyna ; Westergaard, Marie C W ; Arias, Victor ; Pakola, Santeri A ; Met, Özcan ; Donia, Marco ; Hemminki, Akseli ; Monberg, Tine J ; Hendel, Helle W ; Kudling, Tatiana V ; Lorentzen, Cathrine ; Havunen, Riikka ; Sorsa, Suvi ; Eefsen, Rikke L ; Svane, Inge Marie

Tumor-infiltrating lymphocytes (TILs) are effective in the treatment of metastatic melanoma (MM), but toxicity limits its application. TILT-123 (igrelimogene litadenorepvec) is an oncolytic adenovirus producing interleukin-2 (IL-2) and tumor necrosis factor (TNF) upon replication. In this phase 1 trial, 17 patients with metastatic checkpoint inhibitor-resistant melanoma are treated with TILT-123 and TILs without preconditioning chemotherapy or postconditioning IL-2. The treatment is safe and feasible. According to computed tomography (CT), the objective response rate is 11.7% (2/17) and disease control is observed in 35% (6/17), including a partial response lasting >8 months and a durable complete response in a mucosal melanoma patient. According to positron emission tomography (PET), disease control is observed in 7/15 (47%) with minor or partial responses in 4/15 (27%). In the initial TILT-123 monotherapy phase of the trial, disease control is observed in 6/17 (35%) and 10/16 (63%) in CT and PET, respectively. The study demonstrates good tolerability and preliminary efficacy.

2025-01-01·Journal for ImmunoTherapy of Cancer

Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial

Article

作者: Pellinen, Teijo ; Kistler, Claudia ; Quixabeira, Dafne C A ; Pakola, Santeri A ; Cervera-Carrascon, Victor ; Hemminki, Akseli ; Clubb, James H A ; Haybout, Lyna ; Arias, Victor ; Taipale, Kristian ; Santos, Joao M ; Havunen, Riikka ; Kudling, Tatiana V ; van der Heijden, Mirte ; Jirovec, Elise ; Peltola, Katriina ; Sorsa, Suvi ; Alanko, Tuomo ; Sormunen, Jorma

Background:

Oncolytic viruses (OVs) are promising immunotherapeutics to treat immunologically cold tumors. However, research on the mechanism of action of OVs in humans and clinically relevant biomarkers is still sparse. To induce strong T-cell responses against solid tumors, TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2, igrelimogene litadenorepvec) was developed. TILT-123 encodes two transgenes: tumor necrosis alpha (TNFa) and interleukin-2 (IL-2). TUNIMO (NCT04695327) was a phase I clinical trial using TILT-123 in patients with advanced solid tumors aiming to assess the safety, efficacy, and immunological effects of TILT-123. Research presented in this study evaluated the immunological effects of TILT-123 in the TUNIMO trial by using biological samples collected from the patients during the study, with an objective to leverage the findings to develop possible biomarkers of response and gain insights into possible synergistic combination treatments.

Methods:

20 patients with advanced solid tumors were treated with TILT-123. Response to therapy was assessed with contrast-enhanced CT and fluorodeoxyglucose positron emission tomography, along with overall survival (OS) calculation. Biological samples from patients were collected in the form of blood and tumor biopsies. Collected samples were analyzed with immunohistochemistry, transcriptomics, proteomics, and flow cytometry.

Results:

TILT-123 induced cyclical decreases in blood lymphocyte count, and more substantial blood lymphocyte count correlated with better radiographical response and longer OS. Lymphocyte count findings were confirmed with external control dataset of 96 patients. More substantial lymphocyte count change was linked to stronger immune activation in plasma proteome after intravenous TILT-123 and the presence of TILT-123 mRNA in tumors. Regarding other assays. tumor biopsies profiled showed increased amounts of CD8+ T cells, CD4+ T cells and NK cells after intravenous TILT-123, but not after intratumoral TILT-123. Transcriptional differences were seen in tumors after intravenous therapy and intratumoral therapy, with patients benefitting therapy showing stronger downregulation of immune activation at all time points.

Conclusions:

TILT-123 therapy induced accumulation of effector lymphocytes in tumors. Peripheral lymphocyte count decrease is a promising biomarker for assessing oncolytic adenovirus therapy response.

2024-12-01·Immuno-oncology technology

Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma

Article

作者: Quixabeira, D C A ; Westergaard, M C W ; Havunen, R ; Kudling, T ; Donia, M ; Jirovec, E ; Clubb, J ; Ellebaek, E ; Sorsa, S ; von Buchwald, C ; Santos, J M ; Monberg, T J ; Pakola, S ; Cervera-Carrascon, V ; Albieri, B ; Eefsen, R L ; Svane, I M ; Haybout, L ; Hemminki, A ; Kistler, C

Background:

Despite significant advancements in the treatment of malignant melanoma, metastatic mucosal melanoma remains a therapeutic challenge due to its complex pathogenesis, distinct pathological characteristics, and limited response to immunotherapy. Combining different immunotherapeutic approaches offers a potential strategy to address these challenges. Tumor-infiltrating lymphocyte (TIL) therapy and oncolytic virus therapy represent promising treatment modalities that may synergize with each other.

Patient and methods:

We present a case of a 48-year-old woman with metastatic sinonasal mucosal melanoma who achieved a durable complete pathological response following treatment with multiple injections of the oncolytic virus TILT-123 (igrelimogene litadenorepvec) and a single infusion of TILs, without preconditioning chemotherapy or postconditioning interleukin-2.

Results:

Immunohistochemical analysis and single-cell sequencing revealed interesting alterations in injected and noninjected tumors as well as in peripheral blood, during the treatment course, suggesting that TILT-123 facilitated TIL engraftment into the tumor, ultimately leading to a complete response.

Conclusions:

This case underscores the potential of combined immunotherapeutic approaches as a promising strategy for patients with metastatic mucosal melanoma.

项与 Igrelimogene litadenorepvec 相关的新闻（医药）

2025-06-27

·今日头条

ESMO重磅：TIL细胞联合溶瘤病毒，助晚期黑色素瘤患者2年未复发

黏膜黑色素瘤是起源于黏膜覆盖部位黑色素细胞的侵袭性亚型，头颈部为最常见发病部位。其5年总生存率不足25%，且过去数十年间生存数据几乎无改善，复发率高达50%-70%。随着TIL细胞疗法的突破，这一困境迎来转机：2024年ESMO大会报道了一个震撼临床试验案例：一名转移性黏膜黑色素瘤患者接受TIL细胞联合溶瘤腺病毒TILT-123治疗后，实现完全缓解，并持续长达2年之久！ ▲截图源自“ESMO” 从无药可救到完全缓解！TIL细胞联合溶瘤病毒绝杀晚期黑色素瘤，患者存活超2.5年该患者是一位48岁女性，因血管性血友病病史及持续性鼻出血就诊，确诊为晚期鼻窦黏膜黑色素瘤。影像学显示原发性肿瘤几乎完全阻塞左鼻腔，病理检查提示MelanA和S100阳性、BRAF野生型，PD-L1表达<1%。PET/CT发现左侧颈部3个可疑转移淋巴结，切除活检证实为恶性黑色素瘤转移，此时已无法手术切除。患者初始接受伊匹单抗/纳武单抗联合治疗，7个周期后病情进展。停药9周后入组临床试验（NCT04217473），接受单次TIL细胞输注+多轮溶瘤腺病毒TILT-123联合治疗（该病毒经基因改造表达IL-2和TNF-α，可增强免疫细胞浸润）。结果显示：治疗前（基线时），患者存在3处病灶（左鼻腔原发灶、2处颈部淋巴结转移）。TIL细胞联合治疗第36天，患者病情稳定，肿瘤负荷减少14% ，注射/未注射部位病灶分别消退20%/10% 。治疗第78天，肿瘤负荷减少37% ，注射/未注射部位病灶分别消退50%/29% 。 PET扫描显示鼻腔肿瘤葡萄糖摄取增加，但手术切除后病理检查未发现恶性细胞，颈部淋巴结活检亦为阴性，证实达到完全病理缓解（CR）。 ▲图源“ESMO”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除更令人振奋的是，截至目前，患者接受TIL治疗后已存活超过2.5年，影像学及病理学检查均未发现疾病复发迹象，且无需预处理化疗或IL-2维持治疗。小编寄语肿瘤浸润淋巴细胞（TIL）疗法自1988年首次应用于临床以来，已走过30余载的发展历程。相较于其他免疫细胞疗法，TIL疗法独具将患者自身肿瘤组织“变废为宝”的神奇功效，堪称实体瘤治疗领域当之无愧的抗癌黑科技。它既适用于早期癌症患者，可有效预防肿瘤的复发与转移；又能作为晚期患者的挽救性治疗手段，为癌症患者带来一线生机。然而，令人遗憾的是，以往许多患者在手术切除肿瘤组织后，通常仅会提取一小部分用于制作病理蜡块以进行病理诊断，而其余大部分肿瘤组织则会被当作医疗垃圾丢弃，这无疑致使患者体内潜藏的抗癌能力极强的肿瘤浸润淋巴细胞（TIL）被白白浪费。此外，值得关注的是，TILs细胞数量会随着肿瘤的进展而逐渐减少，并且在术后接受辅助性治疗（如放疗、化疗）时，不仅癌细胞会受到杀伤，体内的免疫细胞也可能受到影响。因此，建议患者务必珍惜这或许仅有一次的宝贵抗癌机会。在术前应积极与主治医师进行沟通，尽可能地保留新鲜的肿瘤标本组织，并联系专业机构对TIL细胞进行分离和冻存，做到未雨绸缪。参考资料 [1]Monberg T J,et al. Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma[J]. Immuno-Oncology and Technology, 2024, 24: 100726. https://www.esmoiotech.org/article/S2590-0188(24)00023-6/fulltext 本文为全球肿瘤医生网原创，未经授权严禁转载

细胞疗法免疫疗法临床研究

2025-05-19

·创鉴汇

20家公司获融资！1.32亿欧元支持口服小分子新锐 | 一周融资

据创鉴汇不完全统计，上周（5月12日至5月18日）全球大健康领域共披露融资事件20起，总额超9.5亿美元。从融资轮次来看，35%为早期融资（B轮以前）。Pathos以3.65亿美元D轮融资登顶，Azafaros、Stylus Medicine、Alpheus Medical及Cohere Health的单笔融资超5000万美元。这20家公司中，“AI+生物技术”覆盖小分子抑制剂设计（Pathos）、细胞疗法开发（Somite AI）及计算生物学平台（Pluto Bio）；CGT赛道迭代加速，体内CAR-T（Stylus Medicine）与溶瘤腺病毒疗法（TILT Biotherapeutics）竞逐实体瘤治疗；其他创新药如核素偶联药物（LinqMed）、纤维蛋白靶向抗体（Therini Bio）等拓宽疾病干预边界。#01Pathos AI完成3.65亿美元D轮融资关键词：AI药物最新融资：3.65亿美元D轮5月15日，专注于肿瘤药物研发的生物技术公司Pathos AI宣布完成3.65亿美元D轮融资。本轮资金将用于推进其临床阶段管线及专有多模态数据基础模型的开发。Pathos AI致力于通过整合临床、分子与影像等多维度数据，构建计算驱动的药物开发平台加速肿瘤治疗领域的研发进程。公司核心平台基于多模态数据基础模型，旨在优化临床资产筛选、试验设计及生物标志物发现等关键环节。该模型通过融合大规模临床数据集与分子机制研究，辅助提升药物开发效率。目前，Pathos AI的研发管线聚焦于肿瘤治疗领域，多个临床阶段项目正在推进中。#02Azafaros完成1.32亿欧元B轮融资关键词：口服小分子药物最新融资：1.32亿欧元B轮本轮投资机构：BioGeneration Ventures、Forbion、Jeito Capital、Pictet group、Schroders Capital、Seroba5月13日，Azafaros宣布完成1.32亿欧元B轮融资，将推进其核心管线药物nizubaglustat针对尼曼匹克病C型（NPC）及GM1/GM2神经节苷脂贮积症的两项3期临床研究，并扩展管线至其他适应症。Azafaros成立于2018年，专注于开发罕见溶酶体贮积症的疾病修饰疗法。溶酶体贮积症是一组严重的罕见遗传病，通常会导致进行性神经退行性变。Azafaros的核心候选药物nizubaglustat为口服小分子药物，可穿透血脑屏障，通过双重作用机制调节溶酶体功能，靶向干预脂质代谢异常导致的神经损伤。#03Stylus Medicine正式亮相，获8500万美元A轮融资关键词：体内基因疗法最新融资：8500万美元A轮本轮投资机构：Chugai Venture Fund 、礼来、Khosla Ventures、RA Capital Management、强生创新5月14日，基因疗法公司Stylus Medicine宣布完成8500万美元A融资，将推进其体内基因药物平台开发及管线拓展，重点聚焦体内CAR-T疗法研发。Stylus Medicine专注于利用非病毒递送技术开发精准体内基因疗法。公司核心技术平台将序列特异性基因组整合与细胞靶向脂质纳米粒子（LNP）递送相结合，基于Stylus设计的治疗级重组酶，能够高效、高特异性和高保真地编码多功能多kb有效载荷。该技术旨在实现治疗基因的持久表达与规模化应用。目前，公司研发技术在在肿瘤学、自身免疫、遗传疾病等领域具有潜在的治疗应用。#04Therini Bio获3900万美元A轮融资关键词：单克隆抗体最新融资：3900万美元A轮本轮投资机构：Angelini Ventures、Apollo Health Ventures、礼来、Dementia Discovery Fund、Dolby Family Ventures、赛诺菲风险投资公司等5月14日， Therini Bio宣布完成3900万美元A轮融资，A轮总额达7500万美元。资金将用于推进核心管线药物THN391治疗阿尔茨海默病（AD）及糖尿病黄斑水肿（DME）的1b期临床试验，并支持纤维蛋白/VEGF双特异性抗体的开发。Therini Bio专注于开发靶向纤维蛋白的免疫疗法，聚焦于纤维蛋白介导的神经炎症机制，通过特异性结合纤维蛋白的炎症表位，阻断慢性神经炎症导致的神经元损伤。公司核心候选药物THN391为高亲和力人源化单抗，可选择性抑制纤维蛋白引发的神经炎症而不影响凝血功能。#05TILT Biotherapeutics获2560万美元B轮融资关键词：溶瘤腺病毒免疫疗法最新融资：2560万美元B轮本轮投资机构：Finnish Industry Investment、Lifeline Ventures、Stephen Industries Inc Oy、欧洲创新委员会基金5月13日， TILT Biotherapeutics宣布完成2560万美元（2260万欧元）B轮融资，将推进其核心产品TILT-123在铂类耐药上皮性卵巢癌的2期临床试验，以及联合TILs治疗黑色素瘤的的1b期临床试验。TILT Biotherapeutics专注于溶瘤腺病毒免疫疗法，该腺病毒配备了包括细胞因子在内的分子，可以激活 T 细胞并破坏癌细胞。其专利TILT技术可以通过静脉内、局部或瘤内给药。它改变了肿瘤微环境，通过使“冷”肿瘤变“热”，消除癌症逃避免疫反应的能力，从而增强免疫检查点抑制剂及T细胞疗法的抗肿瘤效应。公司核心管线TILT-123为搭载肿瘤坏死因子（TNF）和白细胞介素-2（IL-2）的溶瘤腺病毒。读者们请星标⭐创鉴汇，第一时间收到推送免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转发/复制至其他平台。转发授权请在「创鉴汇」微信公众号留言联系我们。更多数据内容推荐点击“在看”，分享创鉴汇健康新动态

细胞疗法基因疗法免疫疗法临床3期引进/卖出

2025-05-13

·GlobeNewswire-Health Care

TILT Biotherapeutics Announces Closing of USD 25 Million Series B Financing

Initiates Phase 2 platinum-resistant ovarian cancer trialHELSINKI, May 13, 2025 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (Tiltbio), a clinical-stage biotechnology company developing intravenously delivered cancer immunotherapies, announces it has raised USD 25.6 million (EUR 22.6 million) in a Series B financing. The financing was supported by existing investors; the European Innovation Council (EIC) Fund, Lifeline Ventures, Finnish Industry Investment (TESI), and Stephen Industries Inc Oy. It will support a Phase 2 clinical trial of Tiltbio’s lead product, TILT-123, in patients with platinum-resistant epithelial ovarian cancer, a Phase 1b trial in melanoma in combination with TILs and other Phase 1b trials. The Company recently published data from its Phase 1a clinical trial (PROTA) in platinum-resistant ovarian cancer in Nature Communications (1), which was also presented at AACR (2). The data showed that treatment was well tolerated with an excellent safety profile and promising efficacy observed in some patients. Disease control was achieved in 64% of evaluable patients (9/14) while the overall response rate was 20% at the highest dose level. Median progression-free survival and overall survival were 98 and 190 days respectively. Interim results from ongoing Phase 1b trials are expected to read out in H2 2026. Tiltbio’s founder and CEO, Akseli Hemminki, said: “We are delighted to have secured our Series B financing and thank our investors for their continued support. We’ve been making good progress in ovarian cancer and this financing will support the roll out of our Phase 2 clinical trials. We’re excited to have already opened the first site in the USA and are looking forward to dosing our first patients soon and opening at least five more sites this year.” He continued, “Ovarian cancer continues to be an unmet medical need despite recent therapies being approved. There are no oncolytic viruses or checkpoint inhibitors currently approved for use in this indication. We are committed to our mission to transform the treatment options for patients with ovarian cancer with TILT-123.” TILT-123 (Igrelimogene litadenorepvec), an oncolytic adenovirus armed with tumor necrosis factor (TNF) and interleukin-2 (IL-2), is designed to enhance the efficacy of T-cell therapies and immune checkpoint blockade. Tiltbio has a collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) investigating TILT-123 in combination with KEYTRUDA® (pembrolizumab) in ovarian cancer (NCT05271318). Reference (1) Nature Communications paper: “The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.”(2) American Association for Cancer Research (AACR) Annual Meeting 2025 poster link: ‘Clinical immunology correlates in platinum resistant or refractory ovarian cancer patients treated with chimeric oncolytic adenovirus encoding TNF and IL-2 (TILT-123) in combination with pembrolizumab’ Notes to Editors About TILT Biotherapeutics TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can activate T cells and destroy cancer cells. The company’s patented TILT® technology can be delivered intravenously, locoregionally, or intratumorally. It modifies the tumor microenvironment and has a broader systemic effect. By making cold tumors hot, it eliminates cancer’s ability to evade immune responses, thereby enhancing immune checkpoint inhibitors or T-cell therapies such as tumor infiltrating lymphocyte (TIL) and CAR T therapies. Over eighty patients have been treated in five international trials sponsored by the company with excellent safety profiles and promising initial efficacy responses observed in some patients. The company’s pioneering approach has been recognized by industry leaders. It has two collaborations with MSD (Merck & Co., Inc., Rahway, NJ, USA) investigating TILT-123 in combination with KEYTRUDA® (pembrolizumab) in ovarian cancer (NCT05271318) and in refractory non-small cell lung cancer (NCT06125197). The company is also collaborating with Merck KGaA (Darmstadt, Germany) and investigating TILT-123 in combination with Bavencio® (avelumab). Based in Helsinki, Finland, and with an office in Boston, the company was established over a decade ago as a spin-out from the University of Helsinki. To date Tiltbio has secured over EUR 72 million in financing from investors including the European Innovation Council (EIC) Fund, Lifeline Ventures, Finnish Industry Investment (TESI), Stephen Industries, angel investors, Business Finland, the EIC Accelerator programme, and the U.S. Department of Defense. Media contacts TILT Biotherapeutics COO Aino Kalervoaino@tiltbio.com Scius CommunicationsKatja Stout+447789435990katja@sciuscommunications.com Daniel Gooch+447747875479daniel@sciuscommunications.com

临床2期临床1期临床结果免疫疗法AACR会议

100 项与 Igrelimogene litadenorepvec 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
铂耐药性输卵管癌	临床2期	美国	TILT Biotherapeutics Oy	2022-05-17
铂耐药性输卵管癌	临床2期	芬兰	TILT Biotherapeutics Oy	2022-05-17
铂耐药性卵巢癌	临床2期	美国	TILT Biotherapeutics Oy	2022-05-17
铂耐药性卵巢癌	临床2期	芬兰	TILT Biotherapeutics Oy	2022-05-17
铂类耐药性原发性腹膜癌	临床2期	美国	TILT Biotherapeutics Oy	2022-05-17
铂类耐药性原发性腹膜癌	临床2期	芬兰	TILT Biotherapeutics Oy	2022-05-17
铂敏感性输卵管癌	临床2期	美国	TILT Biotherapeutics Oy	2022-05-17
铂敏感性输卵管癌	临床2期	芬兰	TILT Biotherapeutics Oy	2022-05-17
铂敏感性卵巢癌	临床2期	美国	TILT Biotherapeutics Oy	2022-05-17
铂敏感性卵巢癌	临床2期	芬兰	TILT Biotherapeutics Oy	2022-05-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04217473 (TUNINTIL, ASCO2025)	临床1期	难治性黑色素瘤 anti-Ad neutralizing antibodies \| lymphocyte count	17	TILT-123	製夢積糧蓋鑰遞願膚廠(鑰鹹鬱糧範構齋觸衊淵) = 糧齋積膚顧築築構觸繭顧繭積蓋醖選顧窪鏇醖 (築襯醖積網鹽夢觸製簾 ) 更多	积极	2025-05-30
NCT04217473 (TUNINTIL, ASCO2025)	临床1期	难治性黑色素瘤 anti-Ad neutralizing antibodies \| lymphocyte count	17	oncolytic adenovirus TILT-123 (ACT-TILs)	製夢積糧蓋鑰遞願膚廠(鑰鹹鬱糧範構齋觸衊淵) = 膚範艱鹽膚構鬱積範簾顧繭積蓋醖選顧窪鏇醖 (築襯醖積網鹽夢觸製簾 )	积极	2025-05-30
NCT04695327 \| NCT05271318 \| NCT04217473 (TUNINTIL \| TUNIMO \| PROTA, Pubmed \| J Exp Clin Cancer Res)	临床1期	晚期恶性实体瘤	52	TILT-123 3 × 10^9 VP	簾獵窪糧廠壓鹽鏇膚糧(鏇壓衊鹽選網淵蓋衊襯) = 鑰網遞簾遞淵餘選範簾獵願範蓋鏇壓壓簾簾願 (簾築獵壓顧願獵艱鑰襯 )	积极	2024-11-06
	临床1期	晚期恶性实体瘤	52	TILT-123 4 × 10^12 VP	簾獵窪糧廠壓鹽鏇膚糧(鏇壓衊鹽選網淵蓋衊襯) = 製鹹襯鬱膚廠壓觸衊襯獵願範蓋鏇壓壓簾簾願 (簾築獵壓顧願獵艱鑰襯 )	积极	2024-11-06
NCT05271318 (PROTA, ASCO2024) 人工标引	临床1期	难治性卵巢癌 \| 铂耐药性卵巢癌	14	PembrolizumabIgrelimogene litadenorepvec	壓廠淵醖鏇鹽憲餘襯繭(觸鬱夢糧壓顧襯餘網壓) = Frequent grade 1-4 treatment-related AEs (>30% of patients) were anemia, nausea, lymphocyte count decreased, fever and diarrhea 願選觸齋糧鹹醖願觸壓 (鏇構製繭餘衊積鏇構獵 )	积极	2024-05-24
NCT05271318 (PROTA, ASCO2024) 人工标引	临床1期	难治性卵巢癌 \| 铂耐药性卵巢癌	14	PembrolizumabosomIgrelimogene litadenorepvec		积极	2024-05-24
NCT04695327 \| NCT05271318 \| NCT04217473 (TILT-123, ASCO2024)	临床1期	肿瘤	52	TILT-123	顧齋襯窪願醖鹽餘構構(範製襯製鬱壓構製獵顧) = increased in the patients´ serum 壓醖積鹹選繭艱鹹積範 (齋蓋淵願餘齋鹽廠窪繭 )	积极	2024-05-24
NCT05271318 (AACR2024) 人工标引	临床1期	卵巢癌	15	TILT-123+pembrolizumab	鏇衊壓鏇製襯製艱積積(廠醖艱窪積艱淵鬱膚鏇) = not observed 夢衊製築壓憲窪襯衊鹹 (製醖觸鏇範鹽憲遞築艱 ) 更多	积极	2024-04-05
NCT04695327 (TUNIMO, Pubmed)	临床1期	晚期恶性实体瘤	20	TILT-123	獵餘範夢膚蓋襯齋襯遞(醖範齋淵廠窪範築醖淵) = 製艱衊遞簾艱選壓積築積壓窪積鹽艱鑰廠衊鑰 (顧餘簾壓窪網衊鏇窪獵 )	积极	2024-03-28
NCT04217473 (ESMO_IO 12023 \| ESMO_IO 22023) 人工标引	临床1期	黑色素瘤	16	TILT-123	餘願夢鏇糧糧鏇壓餘憲(壓鏇遞膚網簾蓋艱鬱觸) = The most frequently reported adverse events (AEs) related to TILT-123 were fever (63%) and pain at the injection site (44%) while most frequent AEs related to TIL therapy were fever (50%) and chills (24%). 鏇築醖願艱廠淵願淵築 (繭選觸觸廠網醖選觸蓋 )	积极	2023-12-06
NCT04695327 (TUNIMO , SITC 12023 \| SITC 22023) 人工标引	临床1期	实体瘤	20	TILT-123	餘繭壓構壓鑰網膚齋顧(網夢衊膚窪夢製願鹽鏇) = not observed 積餘廠鏇淵淵範鑰鏇齋 (遞積願艱壓選廠壓獵夢 ) 更多	积极	2023-10-31
NCT04695327 \| NCT05222932 \| NCT05271318 \| NCT04217473 (SITC 12022 \| SITC 22022) 人工标引	临床1期	实体瘤	18	TILT-123	鹹糧製醖築繭遞製構繭(壓淵觸範夢網選餘艱遞) = 鹹廠齋築鹽艱齋膚築願鏇齋餘齋顧選襯繭餘築 (醖窪積糧夢獵積鹹顧鹽 )	积极	2022-11-01